Advanced search
Publication Cover
Leukemia & Lymphoma Volume 55, 2014 - Issue 2
Submit an article Journal homepage
313
Views
10
CrossRef citations to date
0
Altmetric
Research Article

Clinical features of de novo CD25-positive follicular lymphoma

Shin-ichiro FujiwaraDivision of Hematology, Department of MedicineCorrespondence[email protected]
,
Kazuo MuroiDivision of Hematology, Department of Medicine
,
Raine TataraDivision of Hematology, Department of Medicine
,
Tomohiro MatsuyamaDivision of Hematology, Department of Medicine
,
Ken OhmineDivision of Hematology, Department of Medicine
,
Takahiro SuzukiDivision of Hematology, Department of Medicine
,
Masaki MoriDivision of Hematology, Department of Medicine
,
Tadashi NagaiDivision of Hematology, Department of Medicine
,
Akira TanakaDepartment of Pathology, Jichi Medical University, Tochigi, Japan
&
Keiya OzawaDivision of Hematology, Department of Medicine
 show all
Pages 307-313 | Received 02 Dec 2012, Accepted 13 May 2013, Published online: 21 Jun 2013

References

  • A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909–3918.
  • Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447–8452.
  • Lossos IS, Gascoyne RD. Transformation of follicular lymphoma. Best Pract Res Clin Haematol 2011;24:147–163.
  • Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258–1265.
  • Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555–4562.
  • O’Shea D, O’Riain C, Taylor C, et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood 2008;112:3126–3129.
  • de Jong D, Fest T. The microenvironment in follicular lymphoma. Best Pract Res Clin Haematol 2011;24:135–146.
  • Olejniczak K, Kasprzak A. Biological properties of interleukin 2 and its role in pathogenesis of selected diseases—a review. Med Sci Monit 2008;14:RA179–RA189.
  • Kuhn DJ, Dou QP. The role of interleukin-2 receptor alpha in cancer. Front Biosci 2005;10:1462–1474.
  • Nakase K, Kita K, Miwa H, et al. Clinical and prognostic significance of cytokine receptor expression in adult acute lymphoblastic leukemia: interleukin-2 receptor alpha-chain predicts a poor prognosis. Leukemia 2007;21:326–332.
  • Gönen M, Sun Z, Figueroa ME, et al. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood 2012;120: 2297–2306.
  • Fujiwara SI, Muroi K, Hirata Y, et al. Clinical features of de novo CD25(+) diffuse large B-cell lymphoma. Hematology 2013;18:14–19.
  • Bien E, Balcerska A. Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers 2008; 13:1–26.
  • Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
  • Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
  • Kuhn DJ, Smith DM, Pross S, et al. Overexpression of interleukin-2 receptor alpha in a human squamous cell carcinoma of the head and neck cell line is associated with increased proliferation, drug resistance, and transforming ability. J Cell Biochem 2003;89:824–836.
  • Kuhn DJ, Dou QP. Direct inhibition of interleukin-2 receptor alpha-mediated signaling pathway induces G1 arrest and apoptosis in human head-and-neck cancer cells. J Cell Biochem 2005;95: 379–390.
  • Aydin F, Yilmaz M, Ozdemir F, et al. Correlation of serum IL-2, IL-6 and IL-10 levels with International Prognostic Index in patients with aggressive non-Hodgkin's lymphoma. Am J Clin Oncol 2002;25: 570–572.
  • Horn H, Schmelter C, Leich E, et al. Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. Haematologica 2011;96: 1327–1334.
  • Waldmann TA. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene 2007;26:3699–3703.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.